Fund Holdings — BlackBarn Capital Partners LP

Total Portfolio Value:
$172.97M
Total Bought:
$43.46M
Total Sold:
$25.43M
Net Transaction:
+$18.03M
Notable People:
Jeremy Jason Edelstein
Securities
▲▼
SharesValue
Q4 2023
▲▼
Q1 2024
▲▼
Change
▲▼
Q4 2023
▲▼
Q1 2024
▲▼
Weight (%)
▲▼
Change
▲▼
Roivant Sciences Ltd.SHS(ROIV)1,550,0001,900,594+350,594$17.41M$20.03M11.58%+$2.63M
Molina Healthcare, Inc.(MOH)41,90041,9000$15.14M$17.21M9.95%+$2.07M
UnitedHealth Group Incorporated(UNH)26,30030,000+3,700$13.85M$14.84M8.58%+$994.8K
Chord Energy Corporation(CHRD)082,000+82,000$0$14.62M8.45%+$14.62M
CF Industries Holdings, Inc.(CF)150,000150,0000$11.93M$12.48M7.22%+$556.5K
Graphic Packaging Holding Company(GPK)500,000400,000-100,000$12.32M$11.67M6.75%-$653.0K
Knife River Corporation(KNF)135,000135,0000$8.93M$10.95M6.33%+$2.01M
Civitas Resources Inc153,800140,000-13,800$10.52M$10.63M6.14%+$110.6K
Elevance Health, Inc.(ELV)18,00018,0000$8.49M$9.33M5.40%+$845.6K
Amneal Pharmaceuticals, Inc.CL A(AMRX)01,413,297+1,413,297$0$8.56M4.95%+$8.56M
Teva Pharmaceutical Industries LimitedADS(TEVA)0500,000+500,000$0$7.05M4.08%+$7.05M
Interactive Brokers Group, Inc.CL A(IBKR)120,00060,000-60,000$9.95M$6.70M3.88%-$3.25M
RH(RH)41,10017,000-24,100$11.98M$5.92M3.42%-$6.06M
Arbutus Biopharma Corporation(ABUS)02,070,900+2,070,900$0$5.34M3.09%+$5.34M
Bv Finl Inc480,000480,0000$6.81M$4.96M2.87%-$1.85M
Diversified Healthcare TrustCOM SH BEN INT(DHC)1,200,0001,750,000+550,000$4.49M$4.30M2.49%-$183.0K
Privia Health Group, Inc.(PRVA)135,000200,000+65,000$3.11M$3.92M2.27%+$809.0K
Third Coast Bancshares, Inc.(TCBX)0130,781+130,781$0$2.62M1.51%+$2.62M
Advantage Solutions Inc.CL A(ADV)816,606211,704-604,902$2.96M$916.7K0.53%-$2.04M
Optimum Communications, Inc.CL A(OPTU)0250,000+250,000$0$652.5K0.38%+$652.5K
First Bk Williamstown New Je
COM
120,00018,296-101,704$1.76M$251.4K0.15%-$1.51M
Barrick Gold Corp350,0000-350,000$6.33M$0—-$6.33M
Spdr Ser TrS P OILGAS EXP
SP O&G EXPL PRO
40,0000-40,000$5.48M$0—-$5.48M
Page 1 of 1
BlackBarn Capital Partners LP — 13F Holdings — Q1 2024 | TickerTrail